What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.
Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
Lawsuit alleges that patients paid artificially high prices for brand-name Humira, and that they were deprived of the benefits of early, robust competition from biosimilars as a result of wrongful conduct.
Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.
The Pharmacy Times® Biosimilars condition center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of biosimilars, and the newest data from all phases of clinical trials and studies.
Among its other resources are a wealth of videos including interviews with thought leaders and experts in biosimilars, and moderated panel discussions about the best practices and key methods for treating complex cases, utilizing the newest biologic medical products replicating medical products originally manufactured by popular companies.